Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus

Decision Could Speed Up Treatment Approval for Skin-Related Lupus Manifestation NEW YORK, Jan. 28, 2026 /PRNewswire/ -- The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for litifilimab (BIIB059) in...